心筋トロポニン (cTn) 診断薬：予測・機会 (～2025年)

心筋トロポニン (cTn) バイオマーカーは心筋梗塞 (MI) 診断のゴールドスタンダードであり、医療従事者によるcTn診断薬の使用を導いています。また、心臓の不調を訴えて救急外来を受診する患者数が増加しており、心筋梗塞の有無を迅速に判定できるキットに対する救急外来の需要が高まっています。これらの要因が心筋トロポニン (cTn) 診断薬市場の重要な推進要因となっています。

当レポートでは、世界の心筋トロポニン (cTn) 診断薬の市場を調査し、成長への各種影響因子の分析、収益の推移・予測、各種区分・地域別の内訳、競合情勢、収益シェア、成長機会の分析などをまとめています。

目次

戦略的必須要件

• 成長課題
• The Strategic Imperative 8 (TM)
• 戦略的必須要件トップ3の影響
• GrowthPipelineEngine (TM) を推進する成長機会

成長機会の分析

• 心臓バイオマーカー
• 心筋梗塞 (MI) の心臓バイオマーカーのタイムライン
• 心筋トロポニン (cTn)
• MI診断のクリニカルパス
• cTn診断
• 分析範囲
• 分類
• 主要企業
• 成長指標
• 成長促進要因
• 成長抑制要因
• 予測の前提条件
• 収益予測
• 収益予測：製品タイプ別
• 収益予測：地域別
• 収益予測の分析
• 収益予測の分析：地域別
• 競合環境
• 収益シェア
• 収益シェア分析
• 企業マッピング
• 注目の企業

心筋トロポニン (cTn) ：新しい用途

• 高感度トロポニン診断の新たな用途
• MIの新しいバイオマーカー

成長機会の分析：ラボベース検査

• 成長指標
• 収益予測
• 収益予測：地域別
• 予測分析

成長機会の分析：POCT

• 成長指標
• 収益予測：製品タイプ別
• 収益予測：地域別
• 予測分析

成長機会の領域

• 成長機会1：EDの迅速診断
• 成長機会2：hs-cTn POCT
• 成長機会3：デジタルヘルスと診断の相互収束モデル
• 成長機会4：迅速なMI検出のための特異的かつ高感度なアッセイ

次のステップ

Demand for High Sensitivity Point-of-Care Testing Enhance Growth Potential

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.

Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.

In this report, Frost & Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians' offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and hs-cTn tests.

The report also includes the following:

• Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe, Asia-Pacific, and the rest of the world)

• Challenges and drivers

• Competitive landscape, including company market share for lab-based tests and POCT

• Future trends and growth opportunities for stakeholders

North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost & Sullivan's research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Cardiac Troponin (cTn) Diagnostics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Cardiac Biomarkers
• Timeline for Cardiac Biomarkers for MI
• cTns
• Clinical Pathway for MI Diagnosis
• cTn Diagnostics
• cTn Diagnostics (continued)
• Scope of Analysis
• Segmentation
• Competitors
• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Assumptions
• Revenue Forecast
• Revenue Forecast by Product Type
• Revenue Forecast by Region
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)
• Revenue Forecast Analysis by Region
• Competitive Environment
• Revenue Share
• Revenue Share Analysis
• Company Mapping
• Companies to Watch

cTns-New Applications

• High-sensitivity Troponin Diagnostic-Emerging Applications
• New Biomarkers for MI

Growth Opportunity Analysis-Lab-based Tests

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Opportunity Analysis-POCT

• Growth Metrics
• Revenue Forecast by Product Type
• Revenue Forecast by Region
• Forecast Analysis

Growth Opportunity Universe

• Growth Opportunity 1: Rapid Diagnostics for EDs
• Growth Opportunity 1: Rapid Diagnostics for EDs (continued)
• Growth Opportunity 2: hs-cTn POCT
• Growth Opportunity 2: hs-cTn POCT (continued)
• Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model
• Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model (continued)
• Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection
• Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection (continued)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer